High Quality 99% White Powder Nootropics Noopept CAS 157115-85-0

Noopept More Info

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic compound developed in Russia, structurally related to the racetam family but significantly more potent. It is used primarily as a cognitive enhancer and neuroprotective agent.

Mechanism of Action

Noopept’s precise mechanism is not fully elucidated but involves several neurochemical pathways:
Neurotrophic factors: It increases the expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which support neuroplasticity, neuronal survival, and long-term potentiation critical for memory and learning.
Modulation of neurotransmission: Noopept enhances acetylcholine signaling and modulates glutamate transmission, preventing excitotoxicity by reducing excessive glutamate release, thus protecting neurons from damage.
Hypoxia-inducible factor-1 (HIF-1) activation: Noopept increases the DNA-binding activity of HIF-1, a transcription factor involved in cellular adaptive responses to hypoxia, which may contribute to its neuroprotective effects.
Prodrug for cycloprolylglycine: Noopept is rapidly metabolized into cycloprolylglycine, an endogenous neuropeptide with nootropic properties, suggesting much of Noopept’s effects are mediated through this metabolite.
Brain wave modulation: It increases alpha and beta brain wave activity, promoting calmness, creativity, and improved cognitive flow states.

Applications

Cognitive enhancement: Improves memory formation, retention, recall, attention, and learning.
Neuroprotection: Protects neurons from oxidative stress, excitotoxicity, and apoptosis.
Potential therapeutic use in mild cognitive impairment, stroke recovery, and neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) based on preclinical and limited clinical data.
Anxiolytic effects: May reduce anxiety and improve mood.

Pharmacokinetics

Rapidly absorbed orally with peak serum levels within minutes.
Noopept itself is quickly metabolized (within ~25 minutes) and is often undetectable in serum.
Metabolized into cycloprolylglycine and possibly phenylacetic acid; cycloprolylglycine levels increase in brain tissue after administration.
Shows slower elimination in humans compared to animals, with considerable individual variability.
Crosses the blood-brain barrier effectively.

Safety and Side Effects

Generally well tolerated with mild side effects.
Reported adverse effects include sleep disturbances, irritability, and increased blood pressure in some patients.
Limited clinical safety data; drug interactions are not well studied.
One small open-label trial in patients with mild cognitive disorders reported sleep issues (5/31), irritability (3/31), and elevated blood pressure (7/31).
No significant serious adverse effects reported in the limited human studies.